Cyclic RGD peptide-modified liposomal drug delivery system for targeted oral apatinib administration: enhanced cellular uptake and improved therapeutic effects

Apatinib is an oral tyrosine kinase inhibitor, which selectively targets vascular endothelial growth factor receptor 2 and has the potential to treat many tumors therapeutically. Cyclic arginylglycylaspartic acid (cRGD)- and polyethylene glycol (PEG)-modified liposomes (cRGD-Lipo-PEG) were construct...

Descripción completa

Detalles Bibliográficos
Autores principales: Song, Zhiwang, Lin, Yun, Zhang, Xia, Feng, Chan, Lu, Yonglin, Gao, Yong, Dong, Chunyan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5354530/
https://www.ncbi.nlm.nih.gov/pubmed/28331317
http://dx.doi.org/10.2147/IJN.S125573

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5354530/
https://www.ncbi.nlm.nih.gov/pubmed/28331317
http://dx.doi.org/10.2147/IJN.S125573

Ejemplares similares